Stockscreener 앱 받기
8.94
2.83%
-0.26
시장 영업 전:
8.90
-0.04
-0.45%
Regenxbio Inc 주식(RGNX)의 최신 뉴스
This REGENXBIO Insider Increased Their Holding In The Last Year - 富途牛牛
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits
REGENXBIO Inc. (RGNX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome - Yahoo Finance
REGENXBIO CTO Malzahn Craig Retains 81,960 Shares After Forfeiture on September 1, 2026 - Kalkine Media
REGENXBIO CFO Chan Mitchell Forfeits 4,902 Shares at $9.32 Each (NASDAQ: RGNX) - Kalkine Media
REGENXBIO CFO Mitchell Chan Reports Tax-Driven Share Withholding on RSU Vesting - Kalkine Media
How Regenxbio Inc. (RGNX) Affects Rotational Strategy Timing - Stock Traders Daily
REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy - Streetwise Reports
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
People on the Move: Greg Ciongoli Joins REGENXBIO’s Board of Directors - BioBuzz
Regenxbio stock surges on director share purchases By Investing.com - Investing.com Nigeria
Regenxbio stock surges on director share purchases - Investing.com
Why is Regenxbio stock rallying today? - Investing.com
REGENXBIO : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
H.C. Wainwright cuts Regenxbio stock price target on clinical hold - Investing.com
Regenxbio's FDA Hold Threatens Voucher Windfall, Analysts Slash Targets - finance.biggo.com
Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold - Sahm
REGENXBIO Adds Greg Ciongoli to Board Ahead of Commercial Expansion - citybiz
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy - Yahoo Finance
REGENXBIO says FDA places RGX-121 on clinical hold; BLA resubmission not expected soon - TradingView
FDA places clinical hold on Regenxbio’s gene therapy for Hunter Syndrome - kfgo.com
Regenxbio halts BLA resubmission for Hunter syndrome therapy By Investing.com - Investing.com Nigeria
Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling - Barron's
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights - Eastern Progress
REGENXBIO (NASDAQ:RGNX) Trading Down 3.9%Should You Sell? - MarketBeat
RGNX Q2 2026 Earnings: Gene Therapy Developer Posts 626% EPS SurpriseEBITDA Analysis - Vinanet
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX - MarketBeat
Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research - MarketBeat
Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO (RGNX) Pulls Back 2.29% to $10.66 — Gene Therapy Play Tests Key SupportPCR Moving Average - Vinanet
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
(RGNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
HC Wainwright Has Pessimistic View of REGENXBIO Q3 Earnings - MarketBeat
REGENXBIO’s Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) (NASDAQ:RGNX) - Seeking Alpha
H.C. Wainwright lowers Regenxbio stock price target on equity offering By Investing.com - Investing.com UK
RGNX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright lowers Regenxbio stock price target on equity offering - Investing.com
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Dimensional Fund Advisors LP Increases Stock Position in REGENXBIO Inc. $RGNX - MarketBeat
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Regenxbio Inc (RGNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RGNX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
REGENXBIO (RGNX) Stock Drops Despite Profit Surprise And Longer Cash Runway - Sahm
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says - marketscreener.com
REGENXBIO (NASDAQ:RGNX) Shares Down 6.1%Here's Why - MarketBeat
REGENXBIO Price Target Maintained With a $12.00/Share by Barclays - Moomoo
Barclays downgrades Regenxbio stock rating on regulatory uncertainty By Investing.com - Investing.com UK
Barclays Reiterates "Equal Weight" Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
Barclays downgrades Regenxbio stock rating on regulatory uncertainty - Investing.com
Barclays Downgrades REGENXBIO to Equalweight From Overweight, $12 Price Target - marketscreener.com
REGENXBIO Q2 Earnings Call Highlights - MarketBeat
Barclays downgrades Regenxbio stock rating on regulatory concerns By Investing.com - Investing.com Australia
Morgan Stanley Adjusts Price Target on REGENXBIO to $18 From $16, Maintains Overweight Rating - marketscreener.com
Barclays downgrades Regenxbio stock rating on regulatory concerns - Investing.com
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a 101% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
0.86%
0.31%
자본화:
|
볼륨(24시간):